Bio-Rad Laboratories Inc. (BIO)
238.18
-7.03 (-2.87%)
At close: Apr 17, 2025, 3:59 PM
Bio-Rad Laboratories Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics Revenue | 388.8M | 368.6M | 389M | 368.1M | 380.1M | 352.1M | 369.5M | 361.9M | 367.8M | 351.8M | 405M | 372.2M | 380.2M | 358.5M | 359.5M | 322.2M | 283.2M | 340.3M | 379M | 341.8M | 357.1M | 334.1M | 373M | 334M | 354M | 350.8M | 378.4M | 338M | 322.1M | 322.3M | 360.8M | 327.1M | 333.7M | 301.7M | 348.5M | 316.2M | 332.1M | 313.6M | 370.4M | 354.7M | 362.9M | 344.3M | 377.8M | 338.8M | 351.5M | 339.9M | 365.9M | 328.4M | 344M | 327.2M | 674.5M | 341.3M | 348M |
| Clinical Diagnostics Revenue Growth | +5.48% | -5.24% | +5.68% | -3.16% | +7.95% | -4.71% | +2.10% | -1.60% | +4.55% | -13.14% | +8.81% | -2.10% | +6.05% | -0.28% | +11.58% | +13.77% | -16.78% | -10.21% | +10.88% | -4.28% | +6.88% | -10.43% | +11.68% | -5.65% | +0.91% | -7.29% | +11.95% | +4.94% | -0.06% | -10.67% | +10.30% | -1.98% | +10.61% | -13.43% | +10.22% | -4.79% | +5.90% | -15.33% | +4.43% | -2.26% | +5.40% | -8.87% | +11.51% | -3.61% | +3.41% | -7.11% | +11.42% | -4.53% | +5.13% | -51.49% | +97.63% | -1.93% | n/a |
| Life Science Revenue | 260.9M | 241.7M | 291.1M | 263.5M | 300.2M | 323.6M | 359.7M | 317.9M | 322.4M | 347.2M | 326.6M | 373.5M | 334.2M | 366.5M | 428.5M | 324M | 252.1M | 227.2M | 242.1M | 215.7M | 212.4M | 215.7M | 239.5M | 206.6M | 217.8M | 197.8M | 237.9M | 193.6M | 179.4M | 174.3M | 206.7M | 178.1M | 180M | 165.9M | 218.1M | 150.4M | 170.6M | 155.9M | 223.7M | 172.8M | 170.3M | 161.5M | 220.4M | 162.9M | 170.4M | 156.3M | 204.2M | 167M | 162.4M | 154.8M | 353.3M | 171.5M | 169.9M |
| Life Science Revenue Growth | +7.94% | -16.97% | +10.47% | -12.23% | -7.23% | -10.04% | +13.15% | -1.40% | -7.14% | +6.31% | -12.56% | +11.76% | -8.81% | -14.47% | +32.25% | +28.52% | +10.96% | -6.15% | +12.24% | +1.55% | -1.53% | -9.94% | +15.92% | -5.14% | +10.11% | -16.86% | +22.88% | +7.92% | +2.93% | -15.67% | +16.06% | -1.06% | +8.50% | -23.93% | +45.01% | -11.84% | +9.43% | -30.31% | +29.46% | +1.47% | +5.45% | -26.72% | +35.30% | -4.40% | +9.02% | -23.46% | +22.28% | +2.83% | +4.91% | -56.18% | +106.01% | +0.94% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Americas Revenue | 166.6M | 155.4M | 156.6M | 136.6M | 137.3M | 138.3M | 140.2M | 128.3M | 128.5M | 150.9M |
| Americas Revenue Growth | +7.21% | -0.77% | +14.64% | -0.51% | -0.72% | -1.36% | +9.28% | -0.16% | -14.84% | n/a |
| Asia Pacific Revenue | 563M | 639.4M | 688.4M | 546.5M | 505M | 495.5M | 461.3M | 427.1M | 392.2M | 417.5M |
| Asia Pacific Revenue Growth | -11.95% | -7.12% | +25.97% | +8.22% | +1.92% | +7.41% | +8.01% | +8.90% | -6.06% | n/a |
| Europe Revenue | 819.8M | 851.9M | 946.9M | 857.7M | 770.3M | 792M | 758.5M | 742.2M | 763.7M | 901.7M |
| Europe Revenue Growth | -3.77% | -10.03% | +10.40% | +11.35% | -2.74% | +4.42% | +2.20% | -2.82% | -15.30% | n/a |
| United States Revenue | 1.12B | 1.16B | 1.13B | 1B | 899.1M | 863.6M | 800.2M | 770.6M | 735M | 704.9M |
| United States Revenue Growth | -2.91% | +2.20% | +12.52% | +11.76% | +4.11% | +7.92% | +3.84% | +4.84% | +4.27% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 204M | 200.44M | 196.12M | 210.48M | 205.9M | 201.2M | 207.82M | 225.55M | 212.23M | 211.05M | 208.73M | 197.59M | 224.15M | 216.15M | 213.43M | 225.85M | 219.15M | 198.16M | 189.26M | 193.69M | 214.16M | 201.62M | 201.26M | 207.58M | 212.54M | 201.2M | 210.43M | 209.13M | 204.21M | 196.77M | 213.03M | 194.94M | 220.02M | 201.45M | 205.54M | 189.72M | 193.15M | 187.44M | 192.84M | 188.56M |
| Selling, General, and Administrative Revenue Growth | +1.78% | +2.20% | -6.82% | +2.23% | +2.33% | -3.19% | -7.86% | +6.28% | +0.56% | +1.11% | +5.64% | -11.85% | +3.70% | +1.28% | -5.50% | +3.06% | +10.59% | +4.70% | -2.29% | -9.56% | +6.22% | +0.18% | -3.05% | -2.33% | +5.64% | -4.39% | +0.62% | +2.41% | +3.78% | -7.63% | +9.28% | -11.40% | +9.22% | -1.99% | +8.34% | -1.78% | +3.04% | -2.80% | +2.28% | n/a |
| Research and Development Revenue | 79.6M | 91M | 59.3M | 63.98M | 62.21M | 43.53M | 65.04M | 74.95M | 66.2M | 69.95M | 67.03M | 62.54M | 69.87M | 64.48M | 63.39M | 73.91M | 65.77M | 59.55M | 51.98M | 49.3M | 57.07M | 47.94M | 50.12M | 47.58M | 53.07M | 49.24M | 47.45M | 49.43M | 76.82M | 61.37M | 62.62M | 49.49M | 57.54M | 49.92M | 52.17M | 48.59M | 55.89M | 43.34M | 46.55M | 47.2M |
| Research and Development Revenue Growth | -12.52% | +53.44% | -7.30% | +2.83% | +42.90% | -33.07% | -13.22% | +13.22% | -5.36% | +4.35% | +7.18% | -10.49% | +8.36% | +1.72% | -14.23% | +12.39% | +10.44% | +14.55% | +5.44% | -13.61% | +19.03% | -4.35% | +5.35% | -10.36% | +7.78% | +3.78% | -4.00% | -35.66% | +25.17% | -2.00% | +26.54% | -14.00% | +15.26% | -4.31% | +7.38% | -13.06% | +28.96% | -6.90% | -1.39% | n/a |